Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.
